human cathepsin s

MIV-247 is a selective and potent inhibitor of cathepsin S (Kis 2.1, 4.2, and 7.5 nM for human, mouse, and wild monkey cathepsin S, respectively), which attenuates mechanical anomalies in preclinical models of neuropathic pain, and can be used to study cardiac muscle injury.

LY 3000328 (Cathepsin S inhibitor) is a selective inhibitor of cathepsin S with IC50 values ​​of 7.7 and 1.67 nM for human and mouse cathepsin S, respectively. LY 3000328 (Cathepsin S inhibitor) may slow or prevent abdominal aortic aneurysm (AAA) expansion and or reduce the risk of AAA rupture by inhibiting cathepsin S-mediated degradation of extracellular matrix proteins, elastin and collagen.

RO5461111, a highly specific and orally active Cathepsin S antagonist, exhibits potent inhibitory effects with IC50 values of 0.4 nM (human Cathepsin S) and 0.5 nM (murine Cathepsin S), respectively. It effectively suppresses the activation of antigen-specific T cells and B cells, and can ameliorate pulmonary inflammation and lupus nephritis.

JNJ 10329670 is a highly potent (Ki of approximately 30 nM), nonpeptidic, noncovalent inhibitor of human cathepsin S with immunosuppressive activity.

Anti-CTSS Cathepsin S Antibody (Fsn0503h) is a human-origin antibody expressed in CHO cells, targeting CTSS Cathepsin S. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.